Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  anastrozole
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-25 of 78 for your search:
Start Over
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
Phase: Phase IV
Type: Supportive care, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392C00050, SABRE, NCT00082277
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Phase: Phase IV
Type: Diagnostic, Supportive care, Treatment
Status: Closed
Age: 40 to 65
Sponsor: Other
Protocol IDs: 2004/949, NCT00111241
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392NL0002, ARREST, NCT00246961
Arthralgia During Anastrozole Therapy for Breast Cancer
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392L00013, 2005-00-5441-19 EUDRACT number, NCT00323479
Liver Safety Under Upfront Arimidex vs Tamoxifen
Phase: Phase IV
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392L00023, NCT00537771
Pharmacology of Adjuvant Hormonotherapy in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 09 SEIN 09, NCT01127295
Feasibility Study for the Determination of Oxysterols in Patients With Breast Cancer Receiving Hormonal Therapy With Tamoxifen or Not
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11 SEIN 09, NCT01553903
Circulating miRNAs as Biomarkers of Hormone Sensitivity in Breast Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: 11SEIN12, NCT01612871
Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer
Phase: Phase III, Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ROCHE-BO16216, CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672
Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000456382, ACOSOG-Z1031, CALGB-ACOSOG-Z1031, SDC1, NCT00265759
Phase III Randomized, Double-Blind Study of Anastrozole vs Tamoxifen as First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 06/98)
Phase: Phase III
Type: Treatment
Status: Closed
Age: any age
Sponsor: Pharmaceutical / Industry
Protocol IDs: ZENECA-1033IL/0030, NCI-V96-1049
Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999)
Phase: Phase III
Type: Treatment
Status: Closed
Age: Not specified
Sponsor: NCI, Pharmaceutical / Industry
Protocol IDs: RPCI-DS-97-29, ZENECA-9238IL/0021, NCI-G98-1412
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000334899, S0221, U10CA032102, SWOG-S0221, NCT00070564
Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Phase: Phase III
Type: Treatment
Status: Closed
Age: 40 to 70
Sponsor: Other
Protocol IDs: ISRCTN37546358, EU-20226, BIG-5-02, IBCSG-31-03-DCIS, ISRCTN31488319, CRUK-IBIS-II-DCIS, NCT00072462
S0226 Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Postmenopausal
Sponsor: NCI, Other
Protocol IDs: CDR0000349337, U10CA032102, S0226, CAN-NCIC-MAC7, SWOG-S0226, NCT00075764
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
Phase: Phase III
Type: Prevention
Status: Closed
Age: 40 to 70
Sponsor: Other
Protocol IDs: ISRCTN31488319, EU-20227, EUDRACT-2004-003991-12, CRUK-IBIS-IIB, IBCSG-31-03-PREV, NCT00078832
Bisphosphonate and Anastrozole Trial - Bone Maintenance Algorithm Assessment
Phase: Phase III
Type: Supportive care, Treatment
Status: Completed
Age: Postmenopausal
Sponsor: Other
Protocol IDs: ALCC 04.02, NCT00122356
Aromasin Vs Arimidex Study As Initial Hormonal Therapy In Postmenopausal Women With Advanced/Recurrent Breast Cancer
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A5991048, NCT00143390
Fulvestrant With or Without Anastrozole or Exemestane Alone in Treating Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000448616, ICR-CTSU-SOFEA, EU-20531, SSA-04Q200635, ISRCTN44195747, MREC-03677, EUDRACT-2004-000093-30, NCT00253422
Assessing Impact of Loco-regional Treatment on Survival in Metastatic Breast Cancer at Presentation
Phase: Phase III
Type: Treatment
Status: Closed
Age: 21 to 65
Sponsor: Other
Protocol IDs: TMH/153/2004, NCT00193778
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
Phase: Phase III
Type: Treatment
Status: Completed
Age: No age specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D6997L00002, 9238SW/0001, FACT, NCT00256698
Secondary Adjuvant Long Term Study With Arimidex
Phase: Phase III
Type: Treatment
Status: Closed
Age: 80 and under
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392L00016, ABCSG 16, 1033AU/0003, SALSA, NCT00295620
Tamoxifen Versus Anastrozole, Alone or in Combination With Zoledronic Acid
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 19 to 59
Sponsor: Other
Protocol IDs: ABCSG-12, CZOL 446 1B 01, Zol-A-01, NCT00295646
Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Status: Closed
Age: 18 to 75
Sponsor: NCI
Protocol IDs: NCI-2009-00707, CDR0000472066, ECOG-PACCT-1, PACCT-1, U10CA180820, U10CA021115, NCT00310180
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5392NL003, EUDRAct No: 2005-006167-31, NCT00301457
Start Over